Blueprint Medicines (NASDAQ:BPMC) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table summarizes their ...
Editorial Note: Blueprint may earn a commission from affiliate partner links featured here on our site. This commission does not influence our editors' opinions or evaluations. Please view our full ...
Editorial Note: Blueprint may earn a commission from affiliate partner links featured here on our site. This commission does not influence our editors' opinions or evaluations. Please view our full ...
Sen. John Hoeven, R-N.D., talks to an Agri-Pulse reporter while Senate Ag Chairman John Boozman, R-Ark., looks on. (Agri-Pulse photo) Senate Republicans released a new budget blueprint that leaves ...
Sanofi's deal to acquire Blueprint was announced on June 2nd ,for an initial amount of $9.1bn, or $129 per share. Sanoi will acquire Blueprint's approved drug for mastocytosis Aykavit, which earned ...
For the quarter ended June 2023, Blueprint Medicines (BPMC) reported revenue of $57.57 million, up 57.5% over the same period last year. EPS came in at -$2.19, compared to -$2.68 in the year-ago ...
Several Senate Republicans who have withheld their support for the party’s massive tax and spending package signaled on Monday that they weren’t swayed by details unveiled by GOP leaders earlier in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results